Medicine and HealthSignal Transduction and Targeted Therapy
A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
X. Zhang, H. Zhang, et al.
Discover a groundbreaking study that showcases the human antibody 586G, demonstrating robust neutralizing effects against the Delta and Omicron variants of SARS-CoV-2. Remarkably effective through nasal delivery, 586G not only prevents viral replication in lungs but does so with a low daily dose, making it a strong candidate for future COVID-19 treatments. This innovative research was conducted by Xinghai Zhang, Huajun Zhang, Tingting Li, Shaohong Chen, Feiyang Luo, Junhui Zhou, Peiyi Zheng, Shuyi Song, Yan Wu, Tengchuan Jin, Ni Tang, Chengyong Yang, Guofeng Cheng, Ruil Gong, Sandra Chiu, and Ailong Huang.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration
H. Ma, X. Zhang, et al.
Medicine and Health
A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
L. M. Coria, J. M. Rodriguez, et al.
Medicine and Health
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
J. Logue, R. M. Johnson, et al.
Medicine and Health
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
Y. Du, R. Shi, et al.
